Biogen/Sage’s Zuranolone Data May Not Be Enough For Tough Commercial Landscape
Phase III Data Seen As Underwhelming
The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption.
The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption.